title: 3,3'-diindolylmethane rapidly and selectively inhibits hepatocyte growth factor/c-Met signaling in breast cancer cells.
abstract: 3,3'-Diindolylmethane (DIM), an indole derivative from vegetables of the Brassica genus, has antiproliferative activity in breast cancer cells. Part of this activity is thought to be due to DIM inhibition of Akt signaling, but an upstream mechanism of DIM-induced Akt inhibition has not been described. The goals of this study were to investigate the kinetics of inhibition of Akt by physiologically relevant concentrations of DIM and to identify an upstream factor that mediates this effect. Here we report that DIM (5-25 μM) inhibited Akt activation from 30 min to 24h in tumorigenic MDA-MB-231 cells but did not inhibit Akt activation in non-tumorigenic preneoplastic MCF10AT cells. DIM inhibited hepatocyte growth factor (HGF)-induced Akt activation by up to 46%, cell migration by 66% and cell proliferation by up to 54%, but did not inhibit induction of Akt by epidermal growth factor or insulin-like growth factor-1. DIM decreased phosphorylation of the HGF receptor, c-Met, at tyrosines 1234 and 1235, indicating decreased activation of the receptor. This decrease was reversed by pretreatment with inhibitors of p38 or calcineurin. Our results demonstrate the important role of HGF and c-Met in DIM's anti-proliferative effect on breast cancer cells and suggest that DIM could have preventive or clinical value as an inhibitor of c-Met signaling.
authors: Department of Nutritional Science & Toxicology, University of California Berkeley, Berkeley, CA 94720-3104. Electronic address: holly.nicastro@nih.gov.
authors: Holly L
authors: HL
authors: Nicastro
authors: Gary L
authors: GL
authors: Firestone
authors: Leonard F
authors: LF
authors: Bjeldanes
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D017228:Hepatocyte Growth Factor / Q000494:pharmacology / Q000502:physiology; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors*; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors*; D015398:Signal Transduction / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: D007211:Indoles; D017228:Hepatocyte Growth Factor; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met; D051057:Proto-Oncogene Proteins c-akt; C016392:3,3'-diindolylmethane
keywords: 3,3′-diindolylmethane; Akt; Breast cancer; c-Met
references: Oncogene. 2000 Apr 27;19(18):2212-23
references: 10822371
references: Oncogene. 2006 Mar 23;25(13):1922-30
references: 16449979
references: Nutr Cancer. 2002;42(1):1-9
references: 12235639
references: Cancer Lett. 2009 Jul 18;280(1):1-14
references: 19100682
references: Nat Med. 2007 Sep;13(9):1114-9
references: 17694068
references: FASEB J. 2002 Jan;16(1):108-10
references: 11729097
references: Cancer Res. 2005 Jan 1;65(1):364-71
references: 15665315
references: Mol Cancer. 2009 Oct 01;8:81
references: 19796390
references: Carcinogenesis. 1998 Sep;19(9):1631-9
references: 9771935
references: Cancer Res. 2006 May 1;66(9):4880-7
references: 16651444
references: Biochem Pharmacol. 2002 Mar 15;63(6):1085-97
references: 11931841
references: Int J Oncol. 2012 Feb;40(2):436-42
references: 21993423
references: J Nutr. 2010 Jan;140(1):1-6
references: 19889811
references: Carcinogenesis. 2002 Aug;23(8):1297-305
references: 12151347
references: Pharmacol Res. 2007 Mar;55(3):224-36
references: 17317210
references: J Nutr Biochem. 2005 Feb;16(2):65-73
references: 15681163
references: Mol Cancer Ther. 2007 Oct;6(10):2757-65
references: 17913854
references: Immunopharmacol Immunotoxicol. 2011 Dec;33(4):603-8
references: 21428708
references: Mutat Res. 2011 Jul-Oct;728(1-2):47-66
references: 21703360
references: Cancer Res. 2007 Apr 1;67(7):3475-82
references: 17389758
references: Oncogene. 2005 Mar 31;24(14):2343-53
references: 15735741
references: Anticancer Drugs. 2005 Sep;16(8):797-803
references: 16096426
references: J Biol Chem. 1991 Aug 25;266(24):16098-104
references: 1651934
references: J Natl Cancer Inst. 1981 Jun;66(6):1191-308
references: 7017215
references: Drug Metab Dispos. 2004 Jun;32(6):632-8
references: 15155555
references: Carcinogenesis. 2005 Apr;26(4):771-8
references: 15661811
references: Oncogene. 1994 Jan;9(1):49-57
references: 8302603
references: Carcinogenesis. 2006 Mar;27(3):541-50
references: 16199440
references: In Vivo. 2008 Jul-Aug;22(4):441-5
references: 18712169
references: Oncogene. 2003 Nov 20;22(52):8498-508
references: 14627990
references: Mol Cancer Ther. 2008 Feb;7(2):341-9
references: 18281517
references: JAMA. 2001 Jun 20;285(23):2975-7
references: 11410091
references: Proc Natl Acad Sci U S A. 1994 May 24;91(11):4731-5
references: 8197126
references: Semin Cancer Biol. 2001 Apr;11(2):153-65
references: 11322834
references: Int J Cancer. 1991 May 30;48(3):350-4
references: 2040528
references: Cancer Res. 1994 Apr 1;54(7):1630-3
references: 8137271
references: Cancer. 1998 Apr 15;82(8):1513-20
references: 9554529
references: J Nutr. 2009 Apr;139(4):646-52
references: 19244381
references: Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
references: 14685170
references: Biochem Pharmacol. 2009 Sep 1;78(5):469-76
references: 19433067
references: Acta Pharmacol Sin. 2007 Sep;28(9):1274-304
references: 17723163